303 related articles for article (PubMed ID: 26366702)
1. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
Gonzalez-Cao M; Mayo-de-Las-Casas C; Molina-Vila MA; De Mattos-Arruda L; Muñoz-Couselo E; Manzano JL; Cortes J; Berros JP; Drozdowskyj A; Sanmamed M; Gonzalez A; Alvarez C; Viteri S; Karachaliou N; Martin Algarra S; Bertran-Alamillo J; Jordana-Ariza N; Rosell R
Melanoma Res; 2015 Dec; 25(6):486-95. PubMed ID: 26366702
[TBL] [Abstract][Full Text] [Related]
2. Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors.
Sanmamed MF; Fernández-Landázuri S; Rodríguez C; Zárate R; Lozano MD; Zubiri L; Perez-Gracia JL; Martín-Algarra S; González A
Clin Chem; 2015 Jan; 61(1):297-304. PubMed ID: 25411185
[TBL] [Abstract][Full Text] [Related]
3. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
[TBL] [Abstract][Full Text] [Related]
4. Allele specific Taqman-based real-time PCR assay to quantify circulating BRAFV600E mutated DNA in plasma of melanoma patients.
Pinzani P; Salvianti F; Cascella R; Massi D; De Giorgi V; Pazzagli M; Orlando C
Clin Chim Acta; 2010 Sep; 411(17-18):1319-24. PubMed ID: 20576522
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
6. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials.
Santiago-Walker A; Gagnon R; Mazumdar J; Casey M; Long GV; Schadendorf D; Flaherty K; Kefford R; Hauschild A; Hwu P; Haney P; O'Hagan A; Carver J; Goodman V; Legos J; Martin AM
Clin Cancer Res; 2016 Feb; 22(3):567-74. PubMed ID: 26446943
[TBL] [Abstract][Full Text] [Related]
7. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma.
Halait H; Demartin K; Shah S; Soviero S; Langland R; Cheng S; Hillman G; Wu L; Lawrence HJ
Diagn Mol Pathol; 2012 Mar; 21(1):1-8. PubMed ID: 22306669
[TBL] [Abstract][Full Text] [Related]
8. Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.
Gonzalez-Cao M; Mayo de Las Casas C; Jordana Ariza N; Manzano JL; Molina-Vila MÁ; Soriano V; Puertolas T; Balada A; Soria A; Majem M; Montagut C; Muñoz E; Rodriguez-Abreu D; Perez E; Garcia A; Cortes J; Drozdowskyj A; Karachaliou N; Rosell R;
Melanoma Res; 2018 Jun; 28(3):195-203. PubMed ID: 29481492
[TBL] [Abstract][Full Text] [Related]
9. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
10. Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.
Board RE; Ellison G; Orr MC; Kemsley KR; McWalter G; Blockley LY; Dearden SP; Morris C; Ranson M; Cantarini MV; Dive C; Hughes A
Br J Cancer; 2009 Nov; 101(10):1724-30. PubMed ID: 19861964
[TBL] [Abstract][Full Text] [Related]
11. Quantitative analysis of the BRAF
Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of minor BRAF V600 mutation-positive subclones in primary and metastatic melanoma determined by sensitive and quantitative real-time PCR.
Kristensen T; Clemmensen O; Hoejberg L
J Mol Diagn; 2013 May; 15(3):355-61. PubMed ID: 23499336
[TBL] [Abstract][Full Text] [Related]
13. Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients.
Daniotti M; Vallacchi V; Rivoltini L; Patuzzo R; Santinami M; Arienti F; Cutolo G; Pierotti MA; Parmiani G; Rodolfo M
Int J Cancer; 2007 Jun; 120(11):2439-44. PubMed ID: 17315191
[TBL] [Abstract][Full Text] [Related]
14. BRAFV600E detection in melanoma is highly improved by COLD-PCR.
Pinzani P; Santucci C; Mancini I; Simi L; Salvianti F; Pratesi N; Massi D; De Giorgi V; Pazzagli M; Orlando C
Clin Chim Acta; 2011 May; 412(11-12):901-5. PubMed ID: 21262211
[TBL] [Abstract][Full Text] [Related]
15. Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma.
Yancovitz M; Yoon J; Mikhail M; Gai W; Shapiro RL; Berman RS; Pavlick AC; Chapman PB; Osman I; Polsky D
J Mol Diagn; 2007 Apr; 9(2):178-83. PubMed ID: 17384209
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
[TBL] [Abstract][Full Text] [Related]
17. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
18. Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system.
Aung KL; Donald E; Ellison G; Bujac S; Fletcher L; Cantarini M; Brady G; Orr M; Clack G; Ranson M; Dive C; Hughes A
J Mol Diagn; 2014 May; 16(3):343-9. PubMed ID: 24631158
[TBL] [Abstract][Full Text] [Related]
19. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System.
Janku F; Huang HJ; Claes B; Falchook GS; Fu S; Hong D; Ramzanali NM; Nitti G; Cabrilo G; Tsimberidou AM; Naing A; Piha-Paul SA; Wheler JJ; Karp DD; Holley VR; Zinner RG; Subbiah V; Luthra R; Kopetz S; Overman MJ; Kee BK; Patel S; Devogelaere B; Sablon E; Maertens G; Mills GB; Kurzrock R; Meric-Bernstam F
Mol Cancer Ther; 2016 Jun; 15(6):1397-404. PubMed ID: 27207774
[TBL] [Abstract][Full Text] [Related]
20. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]